Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects

L. Groop, L. Luzi, A. Melander, P. H. Groop, K. Ratheiser, D. C. Simonson, R. A. DeFronzo

Research output: Contribution to journalArticle

105 Scopus citations

Abstract

Glyburide (GB) and glipizide (GZ) differ in their pharmacokinetics, but it is not known whether they also differ in mode of action. To examine this question, 10 young healthy subjects and 6 non-insulin-dependent diabetic (NIDDM) patients participated in each of three studies: 1) infusion of saline for 120 min followed by a 100-min hyperglycemic (124 mg/dl) clamp; 2) 120-min primed continuous infusion of GZ followed by a 100-min hyperglycemic clamp; and 3) 120-min primed continuous infusion of GB followed by a 100-min hyperglycemic clamp. The GB and GZ infusions were continued throughout the hyperglycemic clamp. Similar plasma concentrations of GB and GZ were obtained in both groups. All studies were performed with [3-3H]glucose to allow quantification of hepatic glucose production. When administered under basal conditions of glycemia, the acute phase (0-10 min) of plasma insulin and C-peptide increase in both control and NIDDM subjects was twice as great with GZ compared with GB (P <.01). During the hyperglycemic-clamp studies performed in normal subjects, both GB and GZ increased the first- (1.6-fold) and second- (2.2-fold) phase plasma insulin responses more than hyperglycemia alone. During the hyperglycemic clamp in NIDDM subjects, the first-phase plasma insulin response was absent, and the second-phase insulin response was markedly impaired. Neither GB nor GZ improved first-phase insulin secretion in the NIDDM patients. In both NIDDM and control subjects, the effects of hyperglycemia and sulfonylurea drugs (both GB and GZ) on the first- and second-phase plasma insulin responss were simply additive. These results challenge the concept that sulfonylurea agents, when given acutely, potentiate glucose-stimulated insulin secretion. In NIDDM patients, GB decreased basal hepatic glucose production (2.30 ± 0.30 mg·kg-1·min-1) more effectively than GZ (to 0.40 ± 0.12 vs. 0.82 ± 0.11 mg 1/2 .kg-1·min-1, P<.01). These results indicate that the acute administration of GB and GZ to NIDDM subjects has quantitatively different results on hepatic glucose production and acute plasma insulin response to hyperglycemia.

Original languageEnglish (US)
Pages (from-to)1320-1328
Number of pages9
JournalDiabetes
Volume36
Issue number11
DOIs
StatePublished - 1987
Externally publishedYes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects'. Together they form a unique fingerprint.

  • Cite this